Newsroom

Sorted by: Latest
-

Volkswagen Ranked Highest in 2026 Auto Industry Service Scheduling Effectiveness™ Study

AUSTIN, Texas--(BUSINESS WIRE)--Volkswagen ranked highest overall in 2026 auto industry service scheduling effectiveness study, followed by Volvo, Acura, BMW, Mazda, and Nissan...
-

Mitsubishi Electric’s New Plate Heat Exchanger Delivers 3x Conventional Heat Transfer Performance

TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has developed a plate heat exchanger for heat pump cooling and heating equipment with industry-leading heat transfer performance – triple that of conventional models. Specifically, the new heat exchanger reduces the number of plate layers allowing the refrigerant charge to be reduced to approximately one-third that of conventional levels, resulting in lower environmental impact and improved safety. The...
-

Signaloid Announces Appointment of Quantitative Finance and Cloud Veterans to Advisory Board and Senior Commercialization Roles

CAMBRIDGE, England--(BUSINESS WIRE)--British technology company Signaloid today announced the appointment of three distinguished industry veterans to its advisory board and senior leadership roles, to strengthen the commercialization momentum behind its technology: Dr. Han Lee, former Global Head of Quantitative Strategies and Automated Trading for the Fixed Income Division at Morgan Stanley, Dr. Nachiketh Potlapally, former Architect at Oracle Cloud Infrastructure, and Christian Roth, former S...
-

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a 1st-line treatment of patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous non-sm...
-

TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent. These results were presented today d...
-

Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

TOKYO--(BUSINESS WIRE)--Enhertu Demonstrated a Median 14.3 Month Progression-Free Survival as First-Line Therapy in Patients with HER2 Mutant Advanced NSCLC in DESTINY-Lung04...
-

Black & Veatch celebrates more than fifteen years of FLNG innovation, engineering experience and advancement of PRICO liquefaction performance at Gastech 2026

BANGKOK--(BUSINESS WIRE)--Black & Veatch marks more than fifteen years of working in floating LNG (FLNG) this year at Gastech 2026, showcasing dramatic liquefaction performance increases and the launch of the company’s LNG-focused infrastructure intelligence toolset, BVInfraIQ.LNG. These advancements form the basis for the company’s new Advanced Liquefaction Architecture (ALA). ALA encompasses more than 60 years of LNG experience and more than fifteen years of offshore experience achieving...
-

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy versus chemotherapy alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutation-positive non-small cell lung cancer (NSCLC). The data were presented at the International...
-

Corgan Expands Aviation Practice in Asia Pacific with Ben Dawson Hire

SINGAPORE--(BUSINESS WIRE)--Global architecture and design firm Corgan is pleased to announce that Ben Dawson has joined the firm as Aviation & Transportation Studio Leader in its Singapore office. In this role, Dawson will grow Corgan’s presence in the Asia-Pacific region and advise clients as they envision, design and deliver transformative airport environments that enhance passenger experience, operational efficiency, and provide for long-term growth. “Airports in this part of the world...
-

Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Previews the Upcoming 9/19 Event; Highlights FF’s EAI Robotics' Autonomous Perception and 3D Scanning Technology; Adds a New Senior Advisor Focused on Govt. Procurement

LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today shared a weekly business update from YT Jia, Founder and Global CEO of FF.“Hello, everyone. Welcome to Issue 72 of our Weekly Report. Our annual 9/19 event is almost here. On September 19 at 5:00 p.m. Pacific Time, we will hold the FF EAI Robotics "Four-Core Full-Stack AI" Ecosystem New Product Series...